Effects of A Long-Term Use of Carbocysteine on Frequency and Duration of Exacerbations in Patients with Bronchiectasis

Минов, Јордан; Stoleski, Sasho; Petrova, Tatjana; Vasilevska, Kristina; Mijakoski, Dragan; Karadžinska-Bislimovska, Jovanka

doi:10.3889/oamjms.2019.697

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По данным другого рандомизированного исследования показано, что при назначении карбоцистеина 1 125 мг в сутки значительно снижались число и длительность обострений БЭ [67]. По результатам практически всех исследований отмечена высокая безопасность тиол-содержащих препаратов при их длительном приеме.…”

Section: таблица 5 режим дозирования ингаляционных антибактериальных ...unclassified

Bronchiectasis: literature review for preparation of 2024 clinical guidelines

Avdeev,

Kondratyeva,

Kozlov

et al. 2024

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Bronchiectasis, ICD-10 – J47, (BE) is a chronic respiratory disease characterized clinically by cough, sputum production and bronchial infection, and radiographically by abnormal and persistent dilation of the bronchi. Common causes include cystic fibrosis, primary ciliary dyskinesia, immune disorders, systemic inflammatory diseases and infections, and other factors. However, some cases are idiopathic, when the cause cannot be identified. In practice, patients with bronchiectasis are divided into two groups: associated and not associated with cystic fibrosis. The prevalence of the disease varies significantly worldwide; it is not reliably known in the Russian Federation.The aim of the review is to analyze the literature data on modern approaches to the diagnosis of BE and to familiarize readers with diagnostic methods and basic approaches to the treatment.Methods. Data from 77 articles and the expert opinion of specialists providing care to patients with BE were used.Results. The main causes, frequency of occurrence, clinical phenotypes and treatment approaches for BE are described. There are many clinical, laboratory, instrumental and radiological features that provide insight into the etiology of BE. The European consensus is that the goal of treating BE is to restore or maintain normal lung function. There are no randomized trials on the treatment of BE, so all treatment guidelines are based on very low-level evidence or extrapolated from cystic fibrosis guidelines. Recommendations for mucolytic, antibacterial and anti-inflammatory therapy for BE are described, taking into account international and national experience.Conclusion. The development of a new version of clinical guidelines with modern relevant information will improve the diagnosis and treatment of BE in the Russian Federation.

show abstract

Section: таблица 5 режим дозирования ингаляционных антибактериальных ...unclassified

Bronchiectasis: literature review for preparation of 2024 clinical guidelines

Avdeev,

Kondratyeva,

Kozlov

et al. 2024

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

show abstract

“…Currently, carbocysteine in COPD remains a well-tolerated treatment (meaning that it does not require discontinuation of the treatment) with a favorable safety profile that provides symptomatic relief to many patients with mucus production. Mild gastrointestinal effects (e.g., diarrhea, nausea, stomach upset) and headache occurred in about 15% of patients with bronchiectasis during a 3-month treatment with carbocysteine, and these side effects did not require discontinuation of the treatment [74].…”

Section: Limitations and Pitfalls In Carbocysteine Studiesmentioning

confidence: 99%

Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action

et al. 2022

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with a versatile and complicated profile, being the fourth most common single cause of death worldwide. Several research groups have been trying to identify possible therapeutic approaches to treat COPD, such as the use of mucoactive drugs, which include carbocysteine. However, their role in the treatment of patients suffering from COPD remains controversial due to COPD’s multifaceted profile. In the present review, 72 articles, published in peer-reviewed journals with high impact factors, are analyzed in order to provide significant insight and increase the knowledge about COPD considering the important contribution of carbocysteine in reducing exacerbations via multiple mechanisms. Carbocysteine is in fact able to modulate mucins and ciliary functions, and to counteract viral and bacterial infections as well as oxidative stress, offering cytoprotective effects. Furthermore, carbocysteine improves steroid responsiveness and exerts anti-inflammatory activity. This analysis demonstrates that the use of carbocysteine in COPD patients represents a well-tolerated treatment with a favorable safety profile, and might contribute to a better quality of life for patients suffering from this serious illness.

show abstract